500124.IN
Dr. Reddy's Laboratories Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic · IN
Oct 24, 2026, 07:15 UTC
DR REDDYS LABORATORIES LTD said it rose from ninth to eighth place by market share in India's competitive market during the quarter.
Source:Oct 24, 2026, 07:15 UTC
DR REDDYS LABORATORIES LTD reported second-quarter FY2027 revenue down 1.5% to ₹8,671 crore and profit after tax down 36% to ₹925 crore from ₹1,437 crore a year earlier.
Oct 23, 2026, 23:59 UTC
DR REDDYS LABORATORIES LTD said it plans to relaunch semaglutide in 10 markets in November, with Canada expected to account for most of the initial volume.
Source:Oct 23, 2026, 07:30 UTC
DR REDDYS LABORATORIES LTD shares fell 0.72% to ₹1,230.10 on the NSE on October 23, 2026, ahead of its quarterly results.
Source:Oct 8, 2026, 16:10 UTC
India’s Food Safety and Standards Authority issued a notice to the DR REDDYS LABORATORIES LTD over allegedly misleading and ambiguous claims about its GLP-1 supplement.
Sep 18, 2026, 11:30 UTC
Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.
Source:Sep 18, 2026, 03:41 UTC
Dr Reddy's Laboratories signed a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
Sep 15, 2026, 13:00 UTC
Dr. Reddy's Laboratories launched NIVORZ, a nivolumab biosimilar of Bristol Myers Squibb's Opdivo, in India across 12 cancer indications, marking its entry into immuno-oncology.
Source:Sep 15, 2026, 05:00 UTC
The USFDA completed a records assessment at Dr Reddy's Laboratories' API manufacturing facility in Mexico between July 17 and September 8, 2026 and issued a Form FDA 2953 with two observations.
Source:Sep 15, 2026, 04:28 UTC
Dr. Reddy's Laboratories launched a nationwide programme to train over 5,000 Certified Obesity Educators in India.
Source:Sep 14, 2026, 01:30 UTC
Indian benchmark indices ended lower on Friday, with the BSE Sensex falling 120.83 points (0.16%) to 74,781.76 and the NSE Nifty dropping 79.70 points (0.34%) to 23,398.10.
Source:Sep 2, 2026, 19:15 UTC
Aspen Pharmacare is pursuing the market for generic semaglutide, having obtained regulatory approval in Canada and awaiting registration in about 20 countries including Brazil and South Africa.
Source:Aug 4, 2026, 05:39 UTC
Dr. Reddy's Laboratories launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL single-dose vials, a generic equivalent of Bridion, in the United States.
Source:Jul 31, 2026, 14:45 UTC
Levi & Korsinsky announced an investigation into potential securities law violations by Dr. Reddy's Laboratories following a share price decline after the company disclosed a provision for out-of-spec semaglutide batches.
Source:Jul 31, 2026, 11:15 UTC
In July 2026, more than half of BSE 500 stocks underperformed the broader market, with 280 companies declining up to 22%, while benchmark indices ended the month higher.
Jul 30, 2026, 02:45 UTC
The USFDA completed a Pre-Approval Inspection and GMP inspection at Dr Reddy's Laboratories' FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, and issued a Form 483 with three observations.
Source:Jul 22, 2026, 12:28 UTC
Dr. Reddy's Laboratories plans to launch semaglutide in the market before November.
Source:Jul 22, 2026, 10:53 UTC
Dr Reddy's Laboratories reported its quarterly earnings on Wednesday, with profit falling short of expectations due to muted sales of a key generic oncology drug and pricing pressure in the U.S. market.
Jul 20, 2026, 02:22 UTC
Standard Chartered and Dr Reddy's Foundation signed an agreement to train and place 1,250 Persons with Disabilities by March 2028 across five Indian states.
Source:Jul 9, 2026, 03:48 UTC
Dr. Reddy's Laboratories announced that some batches of its semaglutide product do not meet specifications, is investigating the cause, and will delay commercial supply for a period of time.
Source:Jul 2, 2026, 12:00 UTC
Lupin has appointed Bijender Vats as senior vice president and head of human resources.
Source:Jun 29, 2026, 02:30 UTC
The USFDA completed a Pre-License Inspection at Dr Reddy's Laboratories' biologics manufacturing facility in Bachupally, Hyderabad.
Source:Jun 16, 2026, 12:00 UTC
Innoviva Specialty Therapeutics entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories for XACDURO in select international markets.
Source:Jun 13, 2026, 10:22 UTC
Dr. Reddy's Laboratories Ltd. launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States.